Heller Bridgette P 4

What Happened
Bridgette P. Heller, a director of Dexcom, sold 1,012 shares of DXCM on May 12, 2026 at $60.01 per share, generating proceeds of approximately $60,730. The sale was executed in the open market and is categorized as a disposition (sale), which is generally viewed as routine—especially when done under a pre-established plan.

Key Details

• Transaction date: 2026-05-12; Price: $60.01 per share; Shares sold: 1,012; Proceeds: ~$60,730.
• Method: Open-market sale pursuant to a 10b5‑1 trading plan.
• 10b5‑1 plan adoption: Plan was adopted August 14, 2025 (footnote in filing).
• Shares owned after transaction: Not disclosed in the information provided.
• Filing: Form 4 filed May 14, 2026 — within the standard two-business-day reporting window (timely).

Context
Sales made under 10b5‑1 plans are pre-arranged automatic dispositions and are often scheduled to avoid trading on nonpublic information; they do not necessarily indicate the director’s current view of the company’s prospects. For retail investors, purchases typically carry more weight as signaling conviction; routine insider sales—especially under 10b5‑1 plans—are common and frequently relate to diversification or liquidity needs rather than a negative outlook.